<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921424</url>
  </required_header>
  <id_info>
    <org_study_id>V114-030</org_study_id>
    <secondary_id>V114-030</secondary_id>
    <secondary_id>2019-000341-12</secondary_id>
    <nct_id>NCT03921424</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)</brief_title>
  <acronym>PNEU-WAY PED</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Children Infected With Human Immunodeficiency Virus (HIV) (PNEU-WAY PED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of V114 in children infected with HIV. Participants will be randomly assigned
      in a 1:1 ratio to receive either V114 or Prevnar 13™ followed 8 weeks later by a single dose
      of Pneumovax™23. The primary objectives of this study are to evaluate the safety and
      tolerability of V114 in children 6 to 17 years of age inclusive infected with HIV and to
      evaluate the anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG)
      Geometric Mean Concentrations (GMCs) at 30 days following vaccination with V114 or Prevnar
      13™ by each vaccination group. There are no formal hypotheses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">June 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-Site Adverse Event after Vaccination 1</measure>
    <time_frame>Up to Day 14 after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs will consist of redness/erythema, swelling, tenderness/pain, and hard lump/induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event after Vaccination 1</measure>
    <time_frame>Up to Day 14 after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs will consist of muscle pain/myalgia, joint pain/arthralgia, headache, tiredness/fatigue, and hives or welts/urticaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is lifethreatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that are reported to be at least possibly related by the investigator to study vaccination will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Polysaccharide (anti-PnPs) Serotype-specific Immunoglobulin G (IgG) Antibodies after Vaccination 1</measure>
    <time_frame>Day 30</time_frame>
    <description>IgG antibody levels for the serotypes contained in V114 will be determined using a pneumococcal electrochemiluminescence (PnECL) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-Site Adverse Event after Vaccination 2</measure>
    <time_frame>Up to Day 14 after Vaccination 2</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs will consist of redness/erythema, swelling, tenderness/pain, and hard lump/induration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event after Vaccination 2</measure>
    <time_frame>Up to Day 14 after Vaccination 2</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs will consist of muscle pain/myalgia, joint pain/arthralgia, headache, tiredness/fatigue, and hives or welts/urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Pneumococcal Polysaccharide (anti-PnPs) Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) after Vaccination 1</measure>
    <time_frame>Day 30</time_frame>
    <description>OPA for the serotypes contained in V114 will be determined using the Multiplex Opsonophagocytic Assay (MOPA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Pneumococcal Polysaccharide (anti-PnPs) Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) after Vaccination 2</measure>
    <time_frame>Week 12</time_frame>
    <description>OPA for the serotypes contained in V114 will be determined using the MOPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Polysaccharide (anti-PnPs) Serotype-specific IgG Antibodies after Vaccination 2</measure>
    <time_frame>Week 12</time_frame>
    <description>IgG antibody levels for the serotypes contained in V114 will be determined using a PnECL assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 ml dose.</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 6 and 17 years (inclusive) infected with HIV and
             has a Cluster of Differentiation 4+ (CD4+) T-cell count ≥200 cells/µL and plasma HIV
             ribonucleic acid (RNA) &lt;50,000 copies/mL

          -  Is Pneumococcal Conjugate Vaccine (PCV) naïve, previously vaccinated with a &lt;13-valent
             PCV, partially vaccinated with Prevnar 13™, or has a history of previous Prevnar 13™
             vaccination ≥3 years before Visit 2 (Day 1)

          -  Is PnPs vaccine naïve or has a history of 1 previous PnPs vaccination ≥5 years before
             Visit 2 (Day 1)

          -  Female participant: not pregnant, not breastfeeding and 1) not of childbearing
             potential, or 2) of childbearing potential and agrees to practice contraception
             through 6 weeks after administration of study vaccine.

        Exclusion Criteria:

          -  History of World Health Organization (WHO) HIV classification of clinical Stage 4
             disease within the past 12 months

          -  History of invasive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected congenital immunodeficiency (other than HIV infection), functional
             or anatomic asplenia, or history of autoimmune disease

          -  Bleeding disorder contraindicating intramuscular vaccinations

          -  History of malignancy ≤5 years prior to signing informed consent/assent, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

          -  Female participant: positive urine or serum pregnancy test

          -  Expect to receive any pneumococcal vaccine during the study outside of the protocol

          -  Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat
             cancer or other conditions, and interventions associated with organ or bone marrow
             transplantation, or autoimmune disease

          -  Received a blood transfusion or blood products within 6 months of enrollment

          -  Participated in another clinical study of an investigational product within 2 months
             of enrollment

          -  Current user of recreational or illicit drugs or history of drug or alcohol abuse or
             dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit ( Site 0042)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119899700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute (WRHI) ( Site 0043)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113585500ext5912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Clinic Research With UBUNTU ( Site 0045)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219386383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre ( Site 0041)</name>
      <address>
        <city>Paarl</city>
        <state>Western Cape</state>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27218683992</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0063)</name>
      <address>
        <city>Amphoe Mueang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66897112236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University-Pediatrics ( Site 0062)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66894818922</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0064)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6624180545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CM Clinical Trial Unit-CM Clinical Trial Unit ( Site 0061)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66891927004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Instit Dnipropetrovsk Municipal clinical Hospital #21 ( Site 0088)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675638335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Oblast AIDS Center ( Site 0082)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380993348511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Center of Socially Significant Diseases ( Site 0083)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380671404189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Reg Cntr for AIDS Prevention-Control-Outpatient clinic dept ( Site 0086)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnytska Oblast</state>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380672525050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Clinical Children's Hospital ( Site 0089)</name>
      <address>
        <city>Zaporizhzhya</city>
        <state>Zaporizka Oblast</state>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667387295</phone>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal conjugate vaccine (PCV), 15-valent, 22F, 33F</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

